Content |
History
2022: Investing in the production of medical devices for osteosynthesis in the Moscow region
The company "Health +" (part of the GC "Health") in July 2022 launched the production of medical devices for osteosynthesis in the Moscow region. The total volume of investments in the project is estimated at 180 million rubles, and by the end of 2022, 70 million rubles will be allocated for its implementation.
It is noted that the new enterprise will become an import-substituting production and will provide Russian consumers with high-quality high-tech domestic products, which will improve the quality of medical care for the country's population. At the plant with an area of 1.2 thousand square meters. m created 65 jobs, by the end of 2022 this number can be increased to 90.
Health + is engaged in the development and production of unique implants, surgical instruments and materials for traumatology and orthopedics. The company, in particular, imports medical products for osteochondrosis. The implementation of such a project in the Moscow region will close the need for medical devices for osteochondrosis in the domestic market to 40%, the company expects.
Before that there was a foreign investor, it was acquired by our owners. Production has been completely reanimated, all jobs have been restored, "said Ekaterina Zinovieva, Deputy Prime Minister of the Moscow Region, Minister of Investment, Industry and Science of the Moscow Region, at an operational meeting of the governor with the leadership of the regional government and the heads of urban districts. |
Health + is part of the Health group of companies, which is the official distributor and partner of products for traumatology and orthopedics manufactured by Double Medical China (), Smith & Nephew, (Johnson & Johnson both USA) and Regen Lab (). Switzerland The company's portfolio includes a thousand products (by July 2022).[1]